The company and Women & Infants Hospital of Rhode Island are currently evaluating the technology to determine the performance of the test.
The firm sees the Phenoptics system as a highly automated, high-throughput imaging platform that can be used to translate discoveries made on its CODEX device.
The NxClinical software integrates copy number, sequence variant, and allelic change information obtained from microarray and NGS technologies.
Precipio said that its ICE COLD-PCR reagents will be sold with PerkinElmer's DNA/RNA extraction and isolation products.
The firm missed the Wall Street estimates on the top and bottom lines, and it lowered its EPS and adjusted EPS guidance for full-year 2018.
The Lantern Project will screen for patients who may be suffering from Gaucher disease, Fabry disease, Pompe disease, MPS I, or ASMD, and offer confirmatory DNA testing.
The companies will incorporate PerkinElmer's LabChip GX Touch nucleic acid analyzer in the upfront workflow of Agena's MassArray system.
Revenues from the company's diagnostics business and discovery and analytical solutions business each grew 10 percent on an organic basis.
PerkinElmer will offer providers and patients screening for ASAH1 mutations through its PerkinElmer Genomics laboratory unit.
The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.
In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.
The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.
In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.